Literature DB >> 8086856

Production and characterization of an antibody against the human bone GLA protein (BGP/osteocalcin) propeptide and its use in immunocytochemistry of bone cells.

R Kasai1, P Bianco, P G Robey, A J Kahn.   

Abstract

We have generated and characterized an antibody that recognizes the C-terminal sequence of the propeptide of human bone GLA protein (BGP/osteocalcin)(amino acid -26 to -1, with +1 being the amino terminus of the mature protein). The range of sensitivity of the antibody, as determined by enzyme-linked immunosorbent assay (ELISA), was 0.5-250 ng/ml. The antibody effectively recognized pro-BGP in cell layer extracts of transformed cells (KT-005), but did not recognize mature, propeptide-less BGP in the medium from the same cultures. Strong labelling was obtained using this antibody in immunoperoxidase staining or immunofluorescence of both transformed and normal human bone cells in vitro. Monensin significantly altered the intracellular pattern of labelling in immunofluorescence studies, indicating that the recognized antigen was associated with the cellular secretory pathway. We also obtained a specific and strong staining of cells in tissue sections of human fetal bone. Antibodies against the mature protein strongly stained the mineralization front, but did not stain cells to any appreciable level. Newly embedded osteocytes were the predominant cell type stained in such material, suggesting that they may represent the major of BGP in the intact tissue. These observations indicate that BGP synthesis is a late event in osteoblastic development and that antibodies generated against the propeptide sequence are a potentially powerful tool in the analysis of bone tumors and evaluation of osteoblastic differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086856     DOI: 10.1016/s0169-6009(08)80237-1

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  8 in total

1.  Immunocytochemical demonstration of extracellular matrix proteins in isolated osteocytes.

Authors:  E M Aarden; A M Wassenaar; M J Alblas; P J Nijweide
Journal:  Histochem Cell Biol       Date:  1996-11       Impact factor: 4.304

2.  Evaluation of bone turnover in postmenopause, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption.

Authors:  M Takahashi; K Kushida; H Hoshino; T Ohishi; T Inoue
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

3.  The use of BMP-2 coupled - Nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects.

Authors:  Zhong Zheng; Wei Yin; Janette N Zara; Weiming Li; Jinny Kwak; Rachna Mamidi; Min Lee; Ronald K Siu; Richard Ngo; Joyce Wang; Doug Carpenter; Xinli Zhang; Benjamin Wu; Kang Ting; Chia Soo
Journal:  Biomaterials       Date:  2010-09-22       Impact factor: 12.479

4.  Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men.

Authors:  A Falahati-Nini; B L Riggs; E J Atkinson; W M O'Fallon; R Eastell; S Khosla
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

Review 5.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

6.  Pathogenesis of Osteoporosis.

Authors:  Sundeep Khosla
Journal:  Transl Endocrinol Metab       Date:  2010-04

7.  A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.

Authors:  Alison M Boyce; Marilyn H Kelly; Beth A Brillante; Harvey Kushner; Shlomo Wientroub; Mara Riminucci; Paolo Bianco; Pamela G Robey; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-07-17       Impact factor: 5.958

8.  Effects of vibration in forced posture on biochemical bone metabolism indices, and morphometric and mechanical properties of the lumbar vertebra.

Authors:  Qi Chang; Fuling Wei; Li Zhang; Xiaowei Ju; Lvgang Zhu; Changlin Huang; Tao Huang; Xincheng Zuo; Chunfang Gao
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.